
On August 18, 2026, Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum told CNBC that a Federal Trade Commission lawsuit over the company’s data-sharing and subscription practices “misunderstands how the company works.” He defended the company’s compounded GLP-1 drug sales as having helped lower prices for weight-loss treatments. Why This Matters Hims & Hers […]
